Drugs / UCB8600
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04444466 | Jun 2020 → Aug 2021 | chronic urticaria | UCB Biopharma SRL | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UCB8600 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04444466 ↗ |
| Route | Oral | “The purpose of the study is to assess safety, tolerability and pharmacokinetics (PK) of oral UCB8600.” NCT04444466 ↗ |